At the end of a recent FDA advisory committee meeting dealing with the thorny issue of how to design a complicated new study for an approved therapy in a new indication, a senior FDA official was overheard saying: “If you need someone to talk about clinical trials, he’s the guy.”
The person in question is statistician Thomas Fleming (University of Washington) and the trial design under review was for